Viral and Symptom Rebound in Untreated COVID-19 Infection.

ABSTRACT:

Background

There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated outpatients with mild-moderate COVID-19.

Methods

The study population included 568 participants enrolled in the ACTIV-2/A5401 platform trial who received placebo. Anterior nasal swabs were collected for SARS-CoV-2 RNA testing on days 0-14, 21 and 28. Participants recorded the severity of 13 targeted symptoms daily from day 0 to 28. Viral rebound was defined as ≥0.5 log₁₀ viral RNA copies/mL increase and symptom rebound was defined as a 4-point total symptom score increase from

SUBMITTER: Deo R 

PROVIDER: S-EPMC9387151 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature